Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC in HER2-positive urothelial carcinoma
CTR20182469Phase 2Completed
- Sponsor
- RemeGen
- Start
- Jan 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in transitional cell carcinoma (TCC), sponsored by RemeGen. Started Jan 2019; status: completed.
02
Drugs
disitamab vedotin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20182469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182469.